Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation.
Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation.
复制标题
DOI：
10.1038/s41541-018-0061-9
复制
发表时间：
2018
期刊：
影响因子：
9.2
通讯作者：
Barrett ADT
中科院分区：
文献类型：
--
作者：
Barrett ADT
寨卡病毒 (ZIKV) 是一种蚊媒黄病毒，于 20 世纪 40 年代在非洲乌干达首次发现，并于 2015 年 5 月在美洲巴西出现。自 ZIKV 成为重大公共卫生问题以来的 30 个月里，疫苗开发取得了巨大进展，并于 2017 年第四季度发布了三份一期临床试验报告。涉及候选 DNA 和纯化灭活病毒的临床试验疫苗显示，所有疫苗在少数志愿者中都是安全且耐受性良好的，并且所有疫苗均诱导产生中和抗体，尽管这些疫苗因候选疫苗和给药方案而异。这些结果表明寨卡疫苗是可以开发出来的，并且有必要进行二期临床试验。然而，很难比较不同一期研究的结果或与许可的黄病毒疫苗（日本脑炎、蜱传脑炎和黄热病）诱导的中和抗体的结果，因为中和抗体测定各不相同，不幸的是，寨卡病毒中和抗体没有标准。除了临床研究外，非临床开发也继续取得实质性进展，特别是在候选疫苗保护生殖组织的能力以及单克隆抗体用于被动预防的潜在用途方面。
Zika virus (ZIKV), a mosquito-borne flavivirus, was first identified in the 1940s in Uganda in Africa and emerged in the Americas in Brazil in May 2015. In the 30 months since ZIKV emerged as a major public health problem, spectacular progress has been made with vaccine development cumulating with the publication of three reports of phase 1 clinical trials in the 4th quarter of 2017. Clinical trials involving candidate DNA and purified inactivated virus vaccines showed all were safe and well-tolerated in the small number of volunteers and all induced neutralizing antibodies, although these varied by vaccine candidate and dosing regimen. These results suggest that a Zika vaccine can be developed and that phase 2 clinical trials are warranted. However, it is difficult to compare the results from the different phase 1 studies or with neutralizing antibodies induced by licensed flavivirus vaccines (Japanese encephalitis, tick-borne encephalitis, and yellow fever) as neutralizing antibody assays vary and, unfortunately, there are no standards for Zika virus neutralizing antibodies. In addition to clinical studies, substantial progress continues to be made in nonclinical development, particularly in terms of the ability of candidate vaccines to protect reproductive tissues, and the potential use of monoclonal antibodies for passive prophylaxis.
登录
查看更多内容
影响因子：
9.2
作者：
Muthumani K;Griffin BD;Agarwal S;Kudchodkar SB;Reuschel EL;Choi H;Kraynyak KA;Duperret EK;Keaton AA;Chung C;Kim YK;Booth SA;Racine T;Yan J;Morrow MP;Jiang J;Lee B;Ramos S;Broderick KE;Reed CC;Khan AS;Humeau L;Ugen KE;Park YK;Maslow JN;Sardesai NY;Joseph Kim J;Kobinger GP;Weiner DB
通讯作者：
Weiner DB
影响因子：
64.8
作者：
Larocca, Rafael A.;Abbink, Peter;Peron, Jean Pierre S.;Zanotto, Paolo M. de A.;Iampietro, M. Justin;Badamchi-Zadeh, Alexander;Boyd, Michael;Ng'ang'a, David;Kirilova, Marinela;Nityanandam, Ramya;Mercado, Noe B.;Li, Zhenfeng;Moseley, Edward T.;Bricault, Christine A.;Borducchi, Erica N.;Giglio, Patricia B.;Jetton, David;Neubauer, George;Nkolola, Joseph P.;Maxfield, Lori F.;De La Barrera, Rafael A.;Jarman, Richard G.;Eckels, Kenneth H.;Michael, Nelson L.;Thomas, Stephen J.;Barouch, Dan H.
通讯作者：
Barouch, Dan H.
影响因子：
17.1
作者：
Abbink P;Larocca RA;Visitsunthorn K;Boyd M;De La Barrera RA;Gromowski GD;Kirilova M;Peterson R;Li Z;Nanayakkara O;Nityanandam R;Mercado NB;Borducchi EN;Chandrashekar A;Jetton D;Mojta S;Gandhi P;LeSuer J;Khatiwada S;Lewis MG;Modjarrad K;Jarman RG;Eckels KH;Thomas SJ;Michael NL;Barouch DH
通讯作者：
Barouch DH
影响因子：
82.9
作者：
Shan C;Muruato AE;Nunes BTD;Luo H;Xie X;Medeiros DBA;Wakamiya M;Tesh RB;Barrett AD;Wang T;Weaver SC;Vasconcelos PFC;Rossi SL;Shi PY
通讯作者：
Shi PY
DOI：
10.1126/science.aah6157
发表时间：
2016-09-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Abbink P;Larocca RA;De La Barrera RA;Bricault CA;Moseley ET;Boyd M;Kirilova M;Li Z;Ng'ang'a D;Nanayakkara O;Nityanandam R;Mercado NB;Borducchi EN;Agarwal A;Brinkman AL;Cabral C;Chandrashekar A;Giglio PB;Jetton D;Jimenez J;Lee BC;Mojta S;Molloy K;Shetty M;Neubauer GH;Stephenson KE;Peron JP;Zanotto PM;Misamore J;Finneyfrock B;Lewis MG;Alter G;Modjarrad K;Jarman RG;Eckels KH;Michael NL;Thomas SJ;Barouch DH
通讯作者：
Barouch DH